Europe Custom Antibody Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Service ; Type ; Source ; Research Area ; End User

Europe Custom Antibody Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Service ; Type ; Source ; Research Area ; End User

  • July 2021 •
  • 177 pages •
  • Report ID: 6134625 •
  • Format: PDF
The custom antibody market in Europe is expected to grow from US$ 102.5 million in 2021 to US$ 213.7 million by 2028; it is estimated to grow at a CAGR of 11.1% from 2021 to 2028. Advancements in medical technologies support faster and highly efficient discoveries in antibody development, which can be further customized as per the customers’ requirements. Integrating bioinformatics in the discovery of antibodies has led to improvements in custom antibody research. Therefore, artificial intelligence (AI) is likely to emerge as an essential, value addition tool in the discovery of custom antibodies. Oncology research is an emerging field for the application of custom monoclonal antibodies. Most of the clinical trials are performed using monoclonal antibodies derived from rabbits. For instance, anti-VEGF, a humanized anti-vascular growth endothelial factor, derived from rabbit mAb, is currently under clinical studies for the evaluation of its effects on metastatic colorectal cancer and other solid tumors. The anti-VEGF is also under clinical studies for its use in treating age-related macular degeneration. Monoclonal antibodies derived from rabbits are proven as a superior alternative to mouse-derived monoclonal antibodies due to the presence of a larger complementarity determining region (CDR) in the antigen-binding site. In addition, monoclonal antibodies are capable of producing clonal antibodies with higher affinity. Various other sources are being evaluated for custom antibodies discoveries. These discoveries are fueling the custom antibody market growth in Europe.
The market for custom antibody market is segmented into service, type, source, research area, and end user.Based on service, the custom antibody market is segmented into antibody development, antibody production and purification, antibody fragmentation and labelling.

In 2020, the antibody development segment held the largest share of the market, also the same segment is estimated to grow at a significant CAGR due to growing focus of researchers on high-quality custom antibodies for reproducibility during the forecast period.
Italy, Spain, and France are among the severely hit European countries by the COVID-19 pandemic, in terms of cases and death count.Several companies experienced severe revenue losses in the Q4 2019 as well as in the Q1 and Q2 2020.

Hence, the impact of COVID 19 on the European market was immediate and drastic.The custom antibody supply chain, which is already logistically complicated, was introduced with new challenges due to restrictions on transportation and limited availability of workforce.

Thus, the custom antibody market has witnessed shortfall at the beginning of the crisis due to disruptions in supply chain and lowered demand amid lockdown announced by most European countries.However, in the extended period, the requirement for custom antibodies is expected to increase with the supportive efforts by government authorities, and biotech companies and research organization.

In May 2020, ProteoGenix launched the first Human Immune COVID-19 library for the fast development of potent antibodies against SARS-CoV-2. Hence, the European custom antibody market is likely to experience significant growth prospects amid this pandemic and during the forecast period.
The overall Europe custom antibody market size has been derived using both primary and secondary sources.To begin the research process, exhaustive secondary research has been conducted using internal and external sources to obtain qualitative and quantitative information related to the market.

The process also serves the purpose of obtaining overview and forecast for the Europe custom antibody market with respects to all the segments pertaining to the region.Also, multiple primary interviews have been conducted with industry participants and commentators to validate the data, as well as to gain more analytical insights into the topic.

The participants who typically take part in such a process include industry expert such as VPs, business development managers, market intelligence managers, and national sales managers along with external consultants such as valuation experts, research analysts, and key opinion leaders specializing in the Europe Custom antibody market. Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., Merck KGAA, Abcam, Genscript, Agilent Technologies, Inc., and Cell Signaling Technology, Inc. are among a few players operating in the Europe custom antibody market.

We are very sorry, but an error occurred.
Please contact [email protected] if the problem remains.